Cooper Companies Likely to Beat Q3 Earnings Estimate on Lens Demand

The Cooper Companies (COO) is poised to report its Q3 fiscal 2025 results on August 27, with consensus estimates projecting revenues of $982 million (+5.4% YoY) and EPS of $0.92 (+8.2% YoY), building on a history of consistently exceeding earnings forecasts. Growth is anticipated to be largely driven by strong demand within its CooperVision segment, fueled by robust contact lens sales and new product introductions, while the CooperSurgical segment faces a mixed outlook with strength in surgical devices partially offset by continued weakness in its fertility business. A quantitative model, citing a positive Earnings ESP and Zacks Rank #2, indicates a high probability of an earnings beat for COO.

Analysis

The Cooper Companies (COO) is positioned for a bifurcated performance in its upcoming Q3 fiscal 2025 earnings release, with consensus estimates pointing to a 5.4% year-over-year revenue increase to $982 million and an 8.2% rise in EPS to $0.92. The company's larger CooperVision (CVI) segment is expected to be the primary growth engine, fueled by strong, broad-based demand for its contact lens portfolio, including premium MyDay products, double-digit growth in its Clarity line, and market share gains from its Biofinity lenses. Model estimates project CVI's organic sales to increase 6.5% and its operating income to grow a robust 11.7% to $192.9 million. Conversely, the CooperSurgical (CSI) segment faces significant headwinds. While strength is anticipated in surgical devices and from the OVP Surgical acquisition, this is likely to be overshadowed by persistent weakness in the fertility business, particularly in the Asia-Pacific market, and an expected sales decline for PARAGARD following a May 1 price increase. Consequently, the model projects CSI's operating income will decline sharply by 14.4% to $35.4 million. Despite the weakness in CSI, the company's overall outlook is supported by a quantitative model that predicts an earnings beat, citing a positive Earnings ESP of +1.41% and a Zacks Rank #2 (Buy).

Key Decisions for Investors

• Investors should closely monitor the performance divergence between the CooperVision (CVI) and CooperSurgical (CSI) segments, as CVI's projected 11.7% operating income growth must be substantial enough to offset the anticipated 14.4% decline in CSI's operating income.
• Given the positive Earnings ESP and a Zacks Rank #2, which historically signal a higher probability of an earnings beat, investors may anticipate a potential upside surprise driven by outperformance in the core CVI segment.
• Pay particular attention to management's commentary on the fertility business, especially in the Asia-Pacific market, and the demand elasticity for PARAGARD following its recent price increase, as these are key risk factors for the CSI segment.
• The growth rates of key lens brands like MyDay, Clarity, and Biofinity are critical metrics to watch, as their continued momentum is fundamental to the company's overall growth thesis and ability to meet its full-year guidance of 6-7% sales growth for the CVI segment.